Regional Observation of the Metabolic Syndrome (ORSA)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00874952
First received: April 2, 2009
Last updated: February 16, 2010
Last verified: February 2010

April 2, 2009
February 16, 2010
March 2009
February 2010   (final data collection date for primary outcome measure)
  • Prevalence of metabolic syndrome in primary care population [ Time Frame: At visit ] [ Designated as safety issue: No ]
  • Concomitant presence of other cardiovascular (CV) risk factors. [ Time Frame: At visit ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00874952 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Regional Observation of the Metabolic Syndrome
Regional Observation of the Metabolic Syndrome

The aim of the study, is to assess the prevalence of metabolic syndrome in Italy on a regional basis, defined according to National Cholesterol Education Program/Adult Treatment Panel III (NCEP/ATPIII) guidelines criteria.

Not Provided
Observational
Observational Model: Ecologic or Community
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

Primary care clinic

Metabolic Syndrome
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1600
February 2010
February 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Signed informed consent
  • Laboratory analysis (lipidic profile and glycemia) performed in the last year

Exclusion Criteria:

  • Subjects with serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's successful participation in the study
  • Pregnancy or breast feeding
  • Patients enrolled in clinical studies which the aim is to evaluate the efficacy and/or tolerability of anti-hypertensive and/or lipid lowering drugs
Both
40 Years to 74 Years
No
Contact information is only displayed when the study is recruiting subjects
Italy
 
NCT00874952
NIS-CIT-DUM-2007/1
No
Raffaele Sabia/MC MD, AstraZeneca
AstraZeneca
Not Provided
Study Chair: Mario Mangrella AstraZeneca S.p.A.
Study Director: Raffaele Sabia AstraZeneca S.p.A.
AstraZeneca
February 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP